Reliance: a smarter way of regulating medical products-The IPRP survey

被引:10
作者
Doerr, Petra [1 ]
Valentin, Marie [1 ]
Nakashima, Nobumasa [2 ]
Orphanos, Nick [3 ]
Santos, Gustavo [4 ]
Balkamos, Georgios [5 ]
Saint-Raymond, Agnes [6 ]
机构
[1] WHO, Regulat & Safety Unit, Geneva, Switzerland
[2] Pharmaceut & Med Devices Agcy, Tokyo, Japan
[3] Hlth Canada, Ottawa, ON, Canada
[4] ANVISA, Brasilia, DF, Brazil
[5] European Commiss, Brussels, Belgium
[6] European Med Agcy, Amsterdam, Netherlands
关键词
Good manufacturing practices; good regulatory practices; international collaboration; marketing authorization; International Pharmaceutical Regulators Programme; regulatory authorities; regulatory system strengthening; reliance; WHO;
D O I
10.1080/17512433.2021.1865798
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: A survey was conducted among national regulatory authorities' members of the International Pharmaceutical Regulators Programme (IPRP) to collect and share experiences of reliance approaches. Reliance allows formally, or informally, one regulatory authority to use assessments made by other regulatory authorities while remaining responsible for the final decision. Reliance is an essential concept to increase the efficiency of the global regulatory oversight of medical products by national regulatory authorities. Areas covered: This article describes the findings and recommendations from the IPRP survey. It shows that reliance in the area of medical product oversight is broadly accepted. The first part presents the acceptance and reasons for accepting reliance including the need for trust, then gives examples of the most common areas for reliance, and explains the difference between unilateral or reciprocal reliance. Finally, the article analyzes the lessons learned including challenges and opportunities for reliance on regulatory authorities to facilitate patient access in their jurisdictions. Expert opinion: Regulatory reliance facilitates regulatory approvals and allows to use resources in a more efficient way and ultimately serves patients by facilitating earlier access to quality-assured, safe, and effective medicines.
引用
收藏
页码:173 / 177
页数:5
相关论文
共 4 条
[1]  
International Pharmaceutical Regulators Programme, IPRP REL SURV
[2]  
World Health Organization, WHO GLOB BENCHM TOOL
[3]  
World Health Organization, WHO GOOD REL PRACT
[4]  
World Health Organization, 2019, WHO DRAFT POL EV PUB